Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 118Neoplasms 14Neoplasm Metastasis 14Multiple Endocrine Neoplasia Type 1 5Advanced Breast Cancer 5Prostatic Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Breast Cancer Metastatic 3Recurrence 2Lymphoma 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Small Cell Lung Carcinoma 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms by Site 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lethal Congenital Contracture Syndrome 2 1Hyperglycemia 1

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × Fulvestrant × Clear all
NCT01394016 2024-09-19

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
225 enrolled 31 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡